背景:银杏叶制剂(GBLPs)是一类用于辅助治疗缺血性中风(IS)的中草药。最近,已经发表了几项针对IS的GBLPs的系统综述(SRs)和荟萃分析(MA)。
目的:本概述旨在评估相关SR和MA的质量。
方法:PubMed,Embase,科克伦图书馆,WebofScience,中国生物医药,中国国家知识基础设施,万方,和中国科技期刊数据库从成立到2022年12月31日进行了搜索。
方法:纳入了探索GBLPs对IS患者疗效的随机对照试验(RCTs)的SRs和MA。
方法:两名独立的评审员提取数据并评估方法学质量,偏见风险(ROB),报告质量,以及使用衡量工具评估系统评论2(AMSTAR2)的纳入SR和MA的证据的可信度,系统审查中的偏差风险(ROBIS),系统评价和荟萃分析(PRISMA)的首选报告项目,和建议评估的分级,开发和评估(等级),分别。此外,进行描述性分析和数据综合。
结果:本综述包括29个SRs/MA,涉及119个结局。根据AMSTAR2,所有SRs/MA的总体方法学质量都很低,根据ROBIS,28个方法学质量较高。根据PRISMA声明,纳入的SR/MA的报告项目相对完整。基于等级的结果显示,在119个结果中,8人被评为中等质量,24质量低,87质量很低。基于数据综合,与常规治疗结合使用的GBLP在降低神经功能评分方面优于单独的常规治疗。
结论:GBLPs可被认为是IS的有益补充疗法。然而,因为现有证据质量低,高质量的RCT和SRs/MAs有必要进一步评估GBLPs治疗IS的益处。请引用这篇文章:孟TT,你YP,李米,郭JB,SongXB,丁杰,谢XL,李AQ,LiSJ,YinXJ,王普,王正,王BL,他QY。中草药银杏叶制剂治疗缺血性中风:系统评价和荟萃分析概述。JIntegrMed。2024;22(2):163–179。
BACKGROUND: Ginkgo biloba L. preparations (GBLPs) are a class of Chinese herbal medicine used in the adjuvant treatment of ischemic stroke (IS). Recently, several systematic reviews (SRs) and meta-analyses (MAs) of GBLPs for IS have been published.
OBJECTIVE: This
overview aims to assess the quality of related SRs and MAs.
METHODS: PubMed, Embase, Cochrane Library, Web of Science, Chinese Biological Medicine,
China National Knowledge Infrastructure, Wanfang, and Chinese Science and Technology Journals databases were searched from their inception to December 31, 2022.
METHODS: SRs and MAs of randomized controlled trials (RCTs) that explored the efficacy of GBLPs for patients with IS were included.
METHODS: Two independent reviewers extracted data and assessed the methodological quality, risk of bias (ROB), reporting quality, and credibility of evidence of the included SRs and MAs using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2), Risk of Bias in Systematic Reviews (ROBIS), the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), and the Grading of Recommendations Assessment, Development and Evaluation (GRADE), respectively. Additionally, descriptive analysis and data synthesis were conducted.
RESULTS: Twenty-nine SRs/MAs involving 119 outcomes were included in this review. The overall methodological quality of all SRs/MAs was critically low based on AMSTAR 2, and 28 had a high ROB based on the ROBIS. According to the PRISMA statement, the reporting items of the included SRs/MAs are relatively complete. The results based on GRADE showed that of the 119 outcomes, 8 were rated as moderate quality, 24 as low quality, and 87 as very low quality. Based on the data synthesis, GBLPs used in conjunction with conventional treatment were superior to conventional treatment alone for decreasing neurological function scores.
CONCLUSIONS: GBLPs can be considered a beneficial supplemental therapy for IS. However, because of the low quality of the existing evidence, high-quality RCTs and SRs/MAs are warranted to further evaluate the benefits of GBLPs for treating IS. Please cite this article as: Meng TT, You YP, Li M, Guo JB, Song XB, Ding JY, Xie XL, Li AQ, Li SJ, Yin XJ, Wang P, Wang Z, Wang BL, He QY. Chinese herbal medicine Ginkgo biloba L. preparations for ischemic stroke: An
overview of systematic reviews and meta-analyses. J Integr Med. 2024;22(2): 163-179.